Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zongertinib mass balance, metabolism, and bioavailability study in healthy volunteers
NCT05879991Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zongertinib (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Fraction Excreted in Urine and Faeces as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point and Dose-normalised Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 168 hours. Started Aug 2023; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT05879991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879991.